Sugi Predict

Sugi Predict / Compounds / SCHEMBL5659367

SCHEMBL5659367

SCHEMBL5659367

CSc1ncc2cc(-c3c(Cl)cccc3Cl)c(C(=O)O)nc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ FGFR1 P11362 5/20 0.44
▸ SRC P12931 3/20 0.44
▸ AKT1 P31749 4/20 0.43
▸ AKT2 P31751 4/20 0.43
▸ EGFR P00533 3/20 0.43
▸ FGFR2 P21802 2/20 0.43
▸ FGFR4 P22455 2/20 0.43
▸ FGFR3 P22607 2/20 0.43
▸ PRKD3 O94806 1/20 0.43
▸ PRKCG P05129 1/20 0.43
▸ PRKCB P05771 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ PDGFRA P16234 1/20 0.43
▸ PRKCA P17252 1/20 0.43
▸ PRKCH P24723 1/20 0.43
▸ MAPK3 P27361 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ PRKCI P41743 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14607270 0.90 MEN1 (0.44) MEN1KMT2AFGFR1SRCAKT1
SCHEMBL19817044 0.82 FGFR1 (0.50) MEN1KMT2AFGFR1SRCAKT1
SCHEMBL29536557 0.82 FGFR1 (0.50) MEN1KMT2AFGFR1SRCAKT1
SCHEMBL1167993 0.80 FGFR1 (0.69) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL5422413 0.80 FGFR1 (0.57) FGFR1SRCAKT1AKT2EGFR
SCHEMBL3870552 0.80 AKT1 (0.44) MEN1KMT2AFGFR1SRCAKT1
SCHEMBL5583802 0.79 ABL1 (0.61) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL14573080 0.79 FGFR1 (0.43) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4416906 0.79 AKT1 (0.43) MEN1KMT2AAKT1AKT2SMN1; SMN2
SCHEMBL6868503 0.77 KMT2A (0.64) MEN1KMT2ASMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7189732-B2 Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 — — US disclosed
US-7189732-B2 Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 — — US disclosed
US-7189732-B2 Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives HOFFMAN-LA ROCHE INC. (US) 2007-03-13 — — US disclosed
EP-1727819-A1 NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2006-12-06 — — EP disclosed
US-20060014765-A1 Dichloro-phenyl derivatives HOFFMANN-LA ROCHE INC. 2006-01-19 — — US disclosed
WO-2005090344-A1 NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-09-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014765-A1 Dichloro-phenyl derivatives SRC, ABL1, LCK MEN1 4036/4885KMT2A 1593/4885FGFR1 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.